Validation of analytic methods for biomarkers used in drug development
- PMID: 18829475
- PMCID: PMC2744124
- DOI: 10.1158/1078-0432.CCR-07-4535
Validation of analytic methods for biomarkers used in drug development
Abstract
The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.
Figures
Similar articles
-
Biomarker method validation in anticancer drug development.Br J Pharmacol. 2008 Feb;153(4):646-56. doi: 10.1038/sj.bjp.0707441. Epub 2007 Sep 17. Br J Pharmacol. 2008. PMID: 17876307 Free PMC article. Review.
-
Promises of biomarkers in drug development--a reality check.Chem Biol Drug Des. 2007 Jun;69(6):381-94. doi: 10.1111/j.1747-0285.2007.00522.x. Chem Biol Drug Des. 2007. PMID: 17581232 Review.
-
Anticancer drug discovery and development.Adv Exp Med Biol. 2008;610:19-42. doi: 10.1007/978-0-387-73898-7_3. Adv Exp Med Biol. 2008. PMID: 18593013 Review. No abstract available.
-
Validation of biomarker-based risk prediction models.Clin Cancer Res. 2008 Oct 1;14(19):5977-83. doi: 10.1158/1078-0432.CCR-07-4534. Clin Cancer Res. 2008. PMID: 18829476 Free PMC article. Review.
-
Qualification of imaging biomarkers for oncology drug development.Eur J Cancer. 2012 Mar;48(4):409-15. doi: 10.1016/j.ejca.2011.11.037. Epub 2012 Jan 5. Eur J Cancer. 2012. PMID: 22226478 Review.
Cited by
-
Mathematical Models of Tuberculosis Reactivation and Relapse.Front Microbiol. 2016 May 17;7:669. doi: 10.3389/fmicb.2016.00669. eCollection 2016. Front Microbiol. 2016. PMID: 27242697 Free PMC article.
-
Recommendations and best practices for reference standards and reagents used in bioanalytical method validation.AAPS J. 2014 Mar;16(2):352-6. doi: 10.1208/s12248-014-9566-y. Epub 2014 Feb 6. AAPS J. 2014. PMID: 24500277 Free PMC article.
-
A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.J Huntingtons Dis. 2018;7(2):109-135. doi: 10.3233/JHD-170273. J Huntingtons Dis. 2018. PMID: 29614689 Free PMC article. Review.
-
Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach.Biomarkers. 2013 Sep;18(6):467-86. doi: 10.3109/1354750X.2013.821523. Epub 2013 Jul 31. Biomarkers. 2013. PMID: 23902266 Free PMC article.
-
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper.Virchows Arch. 2025 Jul 17. doi: 10.1007/s00428-025-04169-4. Online ahead of print. Virchows Arch. 2025. PMID: 40670724
References
-
- Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004;10:3885–96. - PubMed
-
- Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83. - PubMed
-
- Medicine Zerhouni E. The NIH Roadmap. Science. 2003;302:63–72. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials